Suven Pharmaceuticals Limited
NSE: SUVENPHAR BSE: SUVENPHAR
NSE
1,078.00
-1.20 (-0.11%)
Prev Close
1079.2
Open Price
1060
Volume
1,177,218
Today Low / High
1051 / 1090
52 WK Low / High
598 / 1360
Range
1,024 - 1,132
BSE
1,075.30
0.00 (0.00%)
Prev Close
1075.3
Open Price
1063
Volume
17,906
Today Low / High
1050.45 / 1090
52 WK Low / High
696.55 / 1359
Range
1,022 - 1,129
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 1078 (target range: 1,024 - 1,132), reflecting a change of -1.2 (-0.11119%). On the BSE, it is listed at 1075.3 (target range: 1,022 - 1,129), showing a change of 0 (0%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Suven Pharmaceuticals Limited Graph
Suven Pharmaceuticals Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Suven Pharmaceuticals Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 1,078.00, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 1,075.30 | 1,086.05 | 977.45 - 1,194.66 |
| 1,096.81 | 877.44 - 1,316.17 | ||
| 1,107.56 | 775.29 - 1,439.83 | ||
| Bearish Scenario | 1,075.30 | 1,064.55 | 958.09 - 1,171.00 |
| 1,053.79 | 843.04 - 1,264.55 | ||
| 1,043.04 | 730.13 - 1,355.95 |
Overview of Suven Pharmaceuticals Limited
ISIN
INE03QK01018
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
295,426
Market Cap
412,407,234,624
Last Dividend
0
Official Website
IPO Date
2020-03-09
DCF Diff
825.19
DCF
253
Financial Ratios Every Investor Needs
Stock Dividend of SUVENPHAR
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2022-09-09 | September 09, 22 | 5 | 5 | 2022-09-12 | 2022-10-02 | |
| 2022-05-13 | May 13, 22 | 1 | 1 | 2022-05-17 | 2022-06-08 | |
| 2022-02-15 | February 15, 22 | 2 | 2 | 2022-02-16 | 2022-03-10 | |
| 2021-08-13 | August 13, 21 | 1 | 1 | 2021-08-17 | 2021-09-30 | |
| 2021-02-17 | February 17, 21 | 1 | 1 | 2021-02-18 | 2021-03-11 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 1,197.58 Cr | 305.29 Cr | 892.29 Cr | 0.7451 | 0.00 Cr | 0.00 Cr | 297.71 Cr | 264.77 Cr | 10.52 | 433.76 Cr | 0.2211 |
| 2024-03-31 | 1,051.35 Cr | 448.51 Cr | 602.84 Cr | 0.5734 | 0.00 Cr | 136.80 Cr | 460.76 Cr | 300.28 Cr | 11.80 | 467.72 Cr | 0.2856 |
| 2023-03-31 | 1,340.33 Cr | 585.42 Cr | 754.91 Cr | 0.5632 | 8.59 Cr | 18.93 Cr | 518.80 Cr | 411.29 Cr | 16.16 | 620.26 Cr | 0.3069 |
| 2022-03-31 | 1,289.80 Cr | 555.09 Cr | 734.72 Cr | 0.5696 | 10.35 Cr | 17.06 Cr | 541.63 Cr | 453.80 Cr | 17.83 | 674.01 Cr | 0.3518 |
| 2021-03-31 | 979.94 Cr | 420.20 Cr | 559.73 Cr | 0.5712 | 11.06 Cr | 16.05 Cr | 409.89 Cr | 362.34 Cr | 14.23 | 456.98 Cr | 0.3698 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 85.40 Cr | 3,031.75 Cr | 1,191.11 Cr | 1,696.5800 Cr | 279.07 Cr | 193.67 Cr | 166.57 Cr | 1,250.03 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 365.1900 Cr |
| 2024-03-31 | 47.23 Cr | 2,254.09 Cr | 203.42 Cr | 2,050.6635 Cr | 65.00 Cr | 17.77 Cr | 231.20 Cr | 786.78 Cr | 0.16 Cr | 0.00 Cr | 130.58 Cr | 106.8957 Cr |
| 2023-03-31 | 64.80 Cr | 1,965.74 Cr | 230.56 Cr | 1,735.1843 Cr | 70.34 Cr | 5.54 Cr | 312.81 Cr | 766.22 Cr | 25.57 Cr | 12.86 Cr | 117.10 Cr | 158.7658 Cr |
| 2022-03-31 | 44.56 Cr | 1,829.59 Cr | 302.41 Cr | 1,527.1803 Cr | 97.13 Cr | 52.56 Cr | 283.42 Cr | 561.95 Cr | 34.07 Cr | 37.33 Cr | 117.10 Cr | 210.2940 Cr |
| 2021-03-31 | 7.18 Cr | 1,474.47 Cr | 293.66 Cr | 1,180.8083 Cr | 143.04 Cr | 135.85 Cr | 201.08 Cr | 534.89 Cr | 27.85 Cr | 42.24 Cr | 361.19 Cr | 219.7480 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 288.1600 Cr | -255.3000 Cr | 3.3200 Cr | 132.4500 Cr | 38.3700 Cr | 85.6000 Cr | -155.7100 Cr | 343.9200 Cr | 22.7900 Cr | 0.0000 Cr | 74.1200 Cr |
| 2024-03-31 | 358.4831 Cr | -362.2532 Cr | -13.8023 Cr | 306.6962 Cr | -17.5716 Cr | 47.2312 Cr | -51.7869 Cr | 300.2805 Cr | -6.3512 Cr | 0.0000 Cr | 81.6149 Cr |
| 2023-03-31 | 450.9124 Cr | -194.8422 Cr | -235.8312 Cr | 165.1409 Cr | 20.2390 Cr | 64.8028 Cr | -285.7715 Cr | 559.7298 Cr | -26.3680 Cr | -203.6520 Cr | -29.3932 Cr |
| 2022-03-31 | 330.0002 Cr | -136.2069 Cr | -156.4121 Cr | 254.8135 Cr | 37.3816 Cr | 44.5638 Cr | -75.1867 Cr | 667.5898 Cr | -48.1944 Cr | -101.8260 Cr | -82.3369 Cr |
| 2021-03-31 | 383.4377 Cr | -311.3982 Cr | -76.5529 Cr | 272.5917 Cr | -4.5131 Cr | 7.1822 Cr | -110.8460 Cr | 467.6741 Cr | -42.4248 Cr | -25.4565 Cr | -26.2082 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 402.02 Cr | 134.00 Cr | 268.02 Cr | 0.6667 | 46.78 Cr | 38.91 Cr | 1.55 | 84.13 Cr | 0.0968 |
| 2024-12-31 | 307.15 Cr | 55.63 Cr | 251.52 Cr | 0.8189 | 97.35 Cr | 82.88 Cr | 3.26 | 133.41 Cr | 0.2698 |
| 2024-09-30 | 257.72 Cr | 52.06 Cr | 205.66 Cr | 0.7980 | 87.05 Cr | 81.98 Cr | 3.23 | 118.13 Cr | 0.3181 |
| 2024-06-30 | 230.69 Cr | 149.70 Cr | 80.99 Cr | 0.3511 | 94.39 Cr | 60.77 Cr | 2.39 | 79.93 Cr | 0.2634 |
| 2024-03-31 | 252.93 Cr | 176.89 Cr | 76.04 Cr | 0.3006 | 56.10 Cr | 53.37 Cr | 2.10 | 90.40 Cr | 0.2110 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 85.40 Cr | 205.01 Cr | 290.41 Cr | 284.83 Cr | 166.57 Cr | 888.59 Cr | 1,250.03 Cr | 3,031.75 Cr | 1,191.11 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 655.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,028.42 Cr |
| 2024-09-30 | 36.82 Cr | 619.06 Cr | 672.98 Cr | 185.65 Cr | 215.48 Cr | 1,167.65 Cr | 892.76 Cr | 2,505.56 Cr | 477.14 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 821.13 Cr | 0.00 Cr | 0.00 Cr | 821.13 Cr | 0.00 Cr | 0.00 Cr | -2,050.66 Cr |
| 2024-03-31 | 50.50 Cr | 773.90 Cr | 824.39 Cr | 133.66 Cr | 231.20 Cr | 1,263.19 Cr | 786.78 Cr | 2,254.09 Cr | 203.42 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 82.88 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 82.21 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 60.77 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 53.37 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 46.75 Cr | 25.50 Cr | 0.00 Cr | 0.00 Cr | 25.50 Cr | 86.31 Cr | 60.81 Cr | 0.00 Cr | 25.50 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2020-09-25 | September 25, 20 | 2:1 |
Similar Stocks: Drug Manufacturers - Specialty & Generic
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,733.80 | ₹4,159,871,664,000.00 | ₹2,318,664.00 |
| Divi's Laboratories Limited | DIVISLAB | ₹6,650.00 | ₹1,765,368,850,000.00 | ₹226,973.00 |
| Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,730.60 | ₹1,262,602,917,000.00 | ₹439,520.00 |
| Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,292.10 | ₹1,075,456,274,108.00 | ₹1,386,961.00 |
| Mankind Pharma Limited | MANKIND | ₹2,575.50 | ₹1,062,982,921,380.00 | ₹763,328.00 |
| Zydus Lifesciences Limited | ZYDUSLIFE | ₹995.15 | ₹1,001,349,784,500.00 | ₹775,382.00 |
| Lupin Limited | LUPIN | ₹1,984.60 | ₹906,460,096,200.00 | ₹754,124.00 |
| Aurobindo Pharma Limited | AUROPHARMA | ₹1,158.00 | ₹672,568,716,000.00 | ₹672,249.00 |
| Alkem Laboratories Limited | ALKEM | ₹5,099.60 | ₹609,733,674,000.00 | ₹69,765.00 |
| Glenmark Pharmaceuticals Limited | GLENMARK | ₹2,153.60 | ₹607,748,073,600.00 | ₹786,090.00 |
| Laurus Labs Limited | LAURUSLABS | ₹881.45 | ₹475,603,095,050.00 | ₹5,551,173.00 |
| Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,078.00 | ₹412,407,234,624.00 | ₹1,177,218.00 |
| Ipca Laboratories Limited | IPCALAB | ₹1,529.50 | ₹388,040,268,000.00 | ₹501,348.00 |
| Cohance Lifesciences Limited | COHANCE | ₹997.40 | ₹381,572,333,779.00 | ₹30,739.00 |
| Ajanta Pharma Limited | AJANTPHARM | ₹2,800.50 | ₹349,816,056,000.00 | ₹68,739.00 |
| Piramal Enterprises Limited | PEL | ₹1,287.60 | ₹291,870,592,800.00 | ₹4,377,271.00 |
| J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,782.60 | ₹278,652,466,800.00 | ₹198,162.00 |
| Wockhardt Limited | WOCKPHARMA | ₹1,684.80 | ₹273,744,619,200.00 | ₹253,355.00 |
| Eris Lifesciences Limited | ERIS | ₹1,816.60 | ₹247,415,470,200.00 | ₹258,998.00 |
| AstraZeneca Pharma India Limited | ASTRAZEN | ₹9,340.00 | ₹233,500,000,000.00 | ₹39,783.00 |
| Alembic Pharmaceuticals Limited | APLLTD | ₹1,007.60 | ₹198,056,878,800.00 | ₹43,245.00 |
| Jubilant Pharmova Limited | JUBLPHARMA | ₹1,236.30 | ₹196,919,100,300.00 | ₹1,978,762.00 |
| Neuland Laboratories Limited | NEULANDLAB | ₹13,910.00 | ₹178,463,909,000.00 | ₹72,265.00 |
| NATCO Pharma Limited | NATCOPHARM | ₹973.15 | ₹174,300,896,500.00 | ₹709,365.00 |
| Caplin Point Laboratories Limited | CAPLIPOINT | ₹2,145.80 | ₹163,105,905,860.00 | ₹121,630.00 |
| Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
| Granules India Limited | GRANULES | ₹492.15 | ₹119,417,244,600.00 | ₹954,418.00 |
| Procter & Gamble Health Limited | PGHL | ₹5,947.00 | ₹98,716,631,800.00 | ₹41,877.00 |
| Shilpa Medicare Limited | SHILPAMED | ₹919.15 | ₹89,884,505,735.00 | ₹41,687.00 |
| Strides Pharma Science Limited | STAR | ₹945.35 | ₹87,126,008,445.00 | ₹401,712.00 |
| Aarti Pharmalabs Limited | AARTIPHARM | ₹946.50 | ₹85,785,667,830.00 | ₹174,284.00 |
| FDC Limited | FDC | ₹484.45 | ₹78,873,304,500.00 | ₹30,593.00 |
| Suven Life Sciences Limited | SUVEN | ₹269.30 | ₹58,727,328,200.00 | ₹85,394.00 |
| Innova Captab Limited | INNOVACAP | ₹917.50 | ₹52,503,873,275.00 | ₹36,415.00 |
| Sun Pharma Advanced Research Company Limited | SPARC | ₹151.93 | ₹49,304,627,460.00 | ₹195,988.00 |
| Aarti Drugs Limited | AARTIDRUGS | ₹522.25 | ₹47,665,757,500.00 | ₹446,949.00 |
| Sequent Scientific Limited | SEQUENT | ₹175.86 | ₹44,023,913,100.00 | ₹235,318.00 |
| Unichem Laboratories Limited | UNICHEMLAB | ₹619.85 | ₹43,641,035,130.00 | ₹39,695.00 |
| Hikal Limited | HIKAL | ₹329.80 | ₹40,664,669,800.00 | ₹316,649.00 |
| Gufic Biosciences Limited | GUFICBIO | ₹404.55 | ₹40,567,464,900.00 | ₹352,761.00 |
| RPG Life Sciences Limited | RPGLIFE | ₹2,405.80 | ₹39,789,526,200.00 | ₹52,499.00 |
| Orchid Pharma Limited | ORCHPHARMA | ₹705.15 | ₹35,764,573,365.00 | ₹37,012.00 |
| Morepen Laboratories Limited | MOREPENLAB | ₹59.69 | ₹32,707,374,260.00 | ₹1,444,289.00 |
| Solara Active Pharma Sciences Limited | SOLARA | ₹651.90 | ₹31,390,940,700.00 | ₹124,331.00 |
| Indoco Remedies Limited | INDOCO | ₹324.50 | ₹29,934,443,550.00 | ₹64,322.00 |
| IOL Chemicals and Pharmaceuticals Limited | IOLCP | ₹100.29 | ₹29,437,822,830.00 | ₹15,953,556.00 |
| Alembic Limited | ALEMBICLTD | ₹114.24 | ₹29,334,775,566.00 | ₹212,418.00 |
Key Executives
Vice President of Corporate Affairs
Mr. Sunder Venkatraman
Gender: male
Year Born:
Executive Chairman
Mr. Vivek Sharma CPA
Gender: male
Year Born:
Chief Executive Officer
Dr. Sudhir Kumar Singh Ph.D.
Gender: Not Specified
Year Born: 1965
Chief Quality & Compliance Officer
Dr. K. Nagendra Babu Ph.D.
Gender: Not Specified
Year Born:
Chief Financial Officer
Mr. Himanshu Agarwal
Gender: male
Year Born: 1970
Head of Investor Relations
Ms. Cyndrella Carvalho
Gender: female
Year Born:
Chief Human Resources Officer
Mr. Gaurav Narain Bahadur
Gender: male
Year Born: 1970
Chief Commercial Officer
Dr. Declan Ryan Ph.D.
Gender: Not Specified
Year Born:
MD & Director
Dr. Vetukuri Venkata Naga Kali Vara Prasada Raju Ph.D.
Gender: Not Specified
Year Born:
FAQs about Suven Pharmaceuticals Limited
Who is the CEO of the company?
The CEO is Sudhir Kumar Singh.
What is the current market price of the stock?
The current price is ₹1,078.00.
What is the 52-week price range?
The range is ₹598-1360.
What is the market capitalization of the company?
The market capitalization is ₹41,240.72 crores.
What is the Price-to-Earnings (P/E) ratio?
The P/E ratio is 103.55.
Which sector does the company belong to?
The company operates in the Healthcare sector.
What does the company do?
Overview of Suven Pharmaceuticals Limited (ISIN: INE03QK01018) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹41,240.72 crores and an average daily volume of 295,426 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.